TATDN3 Inhibitors
TATDN3 inhibitors encompass a range of chemical compounds that function through various pathways to ultimately reduce the expression or activity of TATDN3. Compounds like Rapamycin, Temsirolimus, Everolimus, Torin 1, and AZD8055 target the mTOR pathway, a central regulator of cell growth and protein synthesis. These inhibitors bind to and inhibit the function of mTORC1 and/or mTORC2 complexes, resulting in decreased protein synthesis and cell proliferation. The resulting downregulation of these cellular processes is closely associated with a reduction in the expression levels of various proteins, including TATDN3. Notably, the impact on protein synthesis is also shared by LY294002 and Wortmannin, which are PI3K inhibitors that prevent the formation of PIP3, thereby dampening the AKT/mTOR signaling cascade and consequently, the expression of TATDN3.
Furthermore, Triciribine and Spautin-1 indirectly contribute to the suppression of TATDN3 levels by targeting the AKT pathway and autophagy, respectively. Triciribine prevents AKT activation, hindering downstream signaling that includes mTOR pathways, while Spautin-1 disrupts autophagy, potentially affecting the turnover of cellular proteins such as TATDN3. Cell cycleinhibitors like Palbociclib, PD0332991, and Roscovitine, which inhibit CDK4/6 and other CDKs, enforce a cell cycle arrest that indirectly reduces the demand for cellular proteins, including TATDN3, by slowing down cell division and associated biosynthetic processes. The collective action of these inhibitors demonstrates how targeting key regulatory pathways in the cell can lead to an effective decrease in the functional activity of TATDN3, highlighting the interconnectedness of cellular signaling and protein expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically binds to FKBP12 and the complex inhibits mTORC1. Downstream effects of mTORC1 inhibition include reduced protein synthesis and cell growth, leading to decreased expression of multiple genes and proteins, including TATDN3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents the phosphorylation of PIP2 to PIP3, indirectly inhibiting the downstream AKT/mTOR pathway, which can suppress the expression and function of TATDN3 due to its reliance on proper protein synthesis. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. Inhibition of PI3K leads to suppression of the AKT/mTOR pathway, potentially reducing the expression levels of TATDN3 by decreasing overall protein synthesis. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the activation of AKT, thereby inhibiting downstream signaling including the mTOR pathway. This inhibition can lead to reduced expression of TATDN3 due to decreased protein synthesis. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 promotes the degradation of class III PI3K complexes. By inhibiting autophagy, it can indirectly affect the turnover and degradation of proteins, potentially reducing the levels of TATDN3. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that leads to cell cycle arrest. The reduction in cell proliferation can indirectly lead to decreased expression of TATDN3 due to slowed cellular processes and reduced demand for protein synthesis. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a CDK inhibitor which causes cell cycle arrest. It may result in reduced expression of TATDN3 by limiting the cell cycle-dependent protein synthesis. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus selectively inhibits mTORC1, like Rapamycin, and could lead to a decrease in TATDN3 expression by reducing protein synthesis and cell growth. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is an mTOR inhibitor that can inhibit both mTORC1 and mTORC2, leading to a broad suppression of protein synthesis which could reduce TATDN3 levels. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an ATP-competitive inhibitor of mTOR kinase, inhibiting both mTORC1 and mTORC2 complexes. This inhibition could result in decreased expression of TATDN3 by suppressing global protein synthesis. | ||||||